LUTATHERA (Lutetium Lu-177 Dotatate) Patent Expiration, LOE Window & CMS Spending

LUTATHERA (Lutetium Lu-177 Dotatate) by Novartis: FDA Orange Book core substance LOE 2039-01-25, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN208700 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-01-25
Last Listed Patent or Exclusivity Date2039-01-25
Orange Book Patents (*PED Extensions)18 patents (9 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.